LEADER 04594nam  2201189z- 450 
001 9910619467203321
005 20231214132849.0
010   $a3-0365-5281-2
035   $a(CKB)5670000000391602
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93194
035   $a(EXLCZ)995670000000391602
100   $a20202210d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aBrain-Targeted Drug Delivery
210   $cMDPI - Multidisciplinary Digital Publishing Institute$d2022
215   $a1 electronic resource (260 p.)
311   $a3-0365-5282-0 
330   $aBrain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer?s and Parkinson?s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood?brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems.
606   $aTechnology: general issues$2bicssc
610   $adrug delivery into the brain
610   $atransendothelium based on receptor-mediated transcytosis
610   $aimmunotherapy
610   $aAlzheimer's disease
610   $aanti-tau and anti-receptor bispecific monoclonal antibodies
610   $aAlzheimer's disease-relevant tau species
610   $atemporal-spatial pathological A? and tau distribution
610   $ainteractions between A? and tau
610   $atau clearance in microglia
610   $atau clearance in neurons
610   $aliposome
610   $ananoparticle
610   $aseizure
610   $alaser
610   $aultrasound
610   $anaringenin
610   $ananostructured lipid carrier
610   $aintranasal delivery
610   $acentral composite rotatable design
610   $adepression
610   $apomegranate seed oil
610   $anasal delivery system
610   $amemory impairment
610   $amovement impairment
610   $adelivery to brain
610   $aimproved memory
610   $aphospholipid oily gel
610   $ahigh-grade glioma
610   $adiffuse midline glioma
610   $aglioblastoma
610   $aIL-13R?2
610   $aIL-13
610   $aimmunotoxin
610   $atargeted therapy
610   $aGB-13
610   $aIL13.E13K-PE4E
610   $areceptor expression
610   $aacetaminophen
610   $ablood-brain barrier
610   $aclaudin-5
610   $aCNS drug delivery
610   $aopioids
610   $atight junction
610   $amicrodialysis
610   $acerebral open flow microperfusion
610   $aelectrochemical biosensors
610   $amacromolecules
610   $atolcapone
610   $amicroparticles
610   $ananoparticles
610   $aPLGA
610   $aParkinson's disease
610   $anose to brain delivery
610   $agene therapy
610   $apolyplexes
610   $ahyaluronidase
610   $aglycol chitosan
610   $abrain cancer
610   $achemoattractant
610   $aCXCL
610   $aCXCR
610   $aglioblastoma multiforme
610   $a3D cell culture systems
610   $anon-human primate
610   $aconvection-enhanced delivery
610   $aneurosurgery
610   $aoptogenetics
610   $ablood-brain barrier
610   $abrain targeted therapy
610   $adrug delivery
610   $acerebrospinal fluid microcirculation
610   $abrain biodistribution
615  7$aTechnology: general issues
700   $aSousa$b Fla?via$4edt$01323094
702   $aSousa$b Fla?via$4oth
906   $aBOOK
912   $a9910619467203321
996   $aBrain-Targeted Drug Delivery$93035376
997   $aUNINA